Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Tap
    Tap
  2. D'Angelo
    D'Angelo
  3. Chi
    Chi
  4. Antonescu
    Antonescu
  5. Gounder
    Gounder
  6. Kelly
    Kelly
  7. Brennan
    Brennan
  8. Dickson
    Dickson
  9. Hameed
    Hameed
  10. Healey
    Healey

Groups

  1. Department of Medicine (37)
  2. Sarcoma Service (37)
  3. Solid Tumor Oncology Division (37)
  4. GSK Faculty (9)
  5. Hematologic Malignancies, Division of (9)
  6. Tow Center for Developmental Oncology (TCDO) (9)
  7. Surgery (8)
  8. Human Oncology and Pathogenesis Program (7)
  9. Department of Pathology and Laboratory Medicine (6)
  10. Sarcoma Surgeons (5)
Search Within
  1. "Sarcoma Service"
Formats
  1. Journal Article (21)
  2. Meeting Abstract (14)
  3. Editorial (2)
Groups
  1. Department of Medicine (37)
  2. Sarcoma Service (37)
  3. Solid Tumor Oncology Division (37)
  4. GSK Faculty (9)
  5. Hematologic Malignancies, Division of (9)
  6. Tow Center for Developmental Oncology (TCDO) (9)

More Groups

People
  1. William Tap (22)
  2. Sandra D'Angelo (8)
  3. Ping Chi (6)
  4. Ciara Kelly (3)
  5. Cristina Antonescu (3)
  6. Mrinal Gounder (3)

More People

Years
  1. 2024 (8)
  2. 2022 (7)
  3. 2020 (4)
  4. 2019 (2)
  5. 2018 (3)
  6. 2017 (6)

More Years

Publications
  1. Lancet Oncology (13)
  2. Lancet (6)
  3. Value in Health (6)
  4. Journal of Investigative Dermatology (2)
  5. Journal of Molecular Diagnostics (2)
  6. Journal of the American College of Surgeons (2)

More Publications

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): An open-label, randomised clinical trial
    Journal Article

    Mowery, Y. M.; Ballman, K. V.; Hong, A. M.; Schuetze, S. M.; Wagner, A. J.; Monga, V.; Heise, R. S.; Attia, S.; Choy, E.; Burgess, M. A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor
    Meeting Abstract

    Dai, D.; Tecson, K.; Pan; Ye, X.; Tap, W. D.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
    Meeting Abstract

    Desai, J.; Wagner, A. J.; Garcia, I. C.; Cesari, M.; Gordon, M.; Lin, C. C.; Papai, Z.; Ryan, C. W.; Tap, W. D.; Trent, J. C.; more...
    Value in Health (2024)

    Fulltext@MSK | Save
  • Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: An observational cohort study
    Journal Article

    Bertsimas, D.; Margonis, G. A.; Sujichantararat, S.; Koulouras, A.; Ma, Y.; Antonescu, C. R.; Brennan, M. F.; Martín-Broto, J.; Tang, S.; Rutkowski, P.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Gelderblom, H.; Bhadri, V.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; van de Sande, M.; Bernthal, N. M.; López Pousa, A.; Abdul Razak, A.; Italiano, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial
    Journal Article

    D'Angelo, S. P.; Araujo, D. M.; Abdul Razak, A. R.; Agulnik, M.; Attia, S.; Blay, J. Y.; Carrasco Garcia, I.; Charlson, J. A.; Choy, E.; Demetri, G. D.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Evaluation of early dexrazoxane use and cardiotoxicity risk in patients with soft tissue sarcoma treated with anthracyclines
    Meeting Abstract

    Jang, K.; Wallins, J. S.; Movva, S.; Tsay, A.; Liu, J. E.; Yu, A. F.
    Journal of the American College of Cardiology (2024)

    Fulltext@MSK | Save
  • Incremental utility of first-pass perfusion CMR for prognostic risk stratification of cancer-associated cardiac masses
    Journal Article

    Chan, A. T.; Maya, T. R.; Park, C.; Tak, K.; Liberman, N.; Jain, R. H.; Park, M. J.; Park, R. Y.; Grizzard, J.; Kim, G.; more...
    JACC: Cardiovascular Imaging (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes following treatment with vimseltinib for tenosynovial giant cell tumour in a phase 2 expansion study
    Meeting Abstract

    Blay, J. Y.; Gelderblom, H.; Rutkowski, P.; Wagner, A. J.; van de Sande, M.; Stacchiotti, S.; Le Cesne, A.; Palmerini, E.; Vallee, M.; Harrow, B.; more...
    Value in Health (2022)

    Fulltext@MSK | Save
  • Health state utility values and quality of life in patients receiving ripretinib in the phase 3 INVICTUS trial and a real-world evidence study in China
    Meeting Abstract

    Jones, R. L.; Blay, J. Y.; Chi, P.; Bauer, S.; Gelderblom, H.; Shen, L.; He, Y. L.; Heinrich, M. C.; Schöffski, P.; Zalcberg, J. R.; more...
    Value in Health (2022)

    Fulltext@MSK | Save